Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lexicon Pharmaceuticals ( (LXRX) ).
On July 23, 2025, Lexicon Pharmaceuticals, a company listed on The NASDAQ Stock Market, received confirmation from Nasdaq that it has regained compliance with the minimum $1 bid price requirement for its common stock, resolving a previous issue. This development marks a positive step for Lexicon Pharmaceuticals, potentially stabilizing its market position and reassuring stakeholders about the company’s adherence to listing standards.
The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
Spark’s Take on LXRX Stock
According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.
Lexicon Pharmaceuticals’ stock score reflects a mixed financial performance with ongoing profitability challenges and liquidity concerns, balanced by positive technical indicators and a favorable outlook from recent earnings. The Novo Nordisk partnership and financial restructuring are significant positives, but high R&D expenses and a negative P/E ratio highlight valuation risks.
To see Spark’s full report on LXRX stock, click here.
More about Lexicon Pharmaceuticals
Average Trading Volume: 4,364,097
Technical Sentiment Signal: Hold
Current Market Cap: $399.5M
See more insights into LXRX stock on TipRanks’ Stock Analysis page.